Literature DB >> 23684584

The size of the metastatic lymph node is an independent prognostic factor for the patients with cervical cancer treated by definitive radiotherapy.

Sanghyuk Song1, Joo-Young Kim, Yeon-Joo Kim, Heon Jong Yoo, Sun Ho Kim, Suk-Ki Kim, Myong Cheol Lim, Sokbom Kang, Sang-Soo Seo, Sang-Yoon Park.   

Abstract

BACKGROUND AND
PURPOSE: Lymph node (LN) metastasis is a well-known prognostic factor of the cervical cancer. In the current study, the size of metastatic LN was evaluated for its significance in the patients treated with definitive radiotherapy.
MATERIALS AND METHODS: LN metastasis was evaluated for the 268 consecutive patients. The short-axis diameters of the largest LN were measured on magnetic resonance images for the 155 patients with LN metastasis. All the patients were classified into three groups: the negative lymphadenopathy (group N), the small (<15mm) lymphadenopathy (group SP), and the large (≥15mm) lymphadenopathy (group LP).
RESULTS: Patients in the group LP showed significantly lower survival rates than the groups N and SP (5-year overall survival rates of 89%, 82%, and 58%, for groups N, SP, and LP, respectively, P<0.001; 5-year disease-free survival rates of 80%, 67%, and 50%, respectively, P<0.001). Regarding the pattern of failure, patients in the group LP showed inferior regional control rates and higher distant metastasis.
CONCLUSION: The current study shows that the patients with large metastatic LNs are at increased risk of dying from early distant metastasis with substantial number of combined regional failures. Adoption of more effective systemic treatment as well as high radiotherapy dose for LNs may improve cure rates for these patients.
Copyright © 2013. Published by Elsevier Ireland Ltd.

Entities:  

Keywords:  Cervical cancer; Lymph node size; Radiotherapy; Survival

Mesh:

Year:  2013        PMID: 23684584     DOI: 10.1016/j.radonc.2013.04.015

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  11 in total

1.  Magnetic resonance image-guided brachytherapy for cervical cancer : Prognostic factors for survival.

Authors:  Yeon-Joo Kim; Joo-Young Kim; Youngkyong Kim; Young Kyung Lim; Jonghwi Jeong; Chiyoung Jeong; Meyoung Kim; Myong Cheol Lim; Sang-Soo Seo; Sang-Yoon Park
Journal:  Strahlenther Onkol       Date:  2016-10-12       Impact factor: 3.621

2.  Whether individualized dose escalation should be recommended for lymph nodes with different sizes in the definitive radiotherapy of cervical cancer?

Authors:  Xiaojuan Lv; Huiting Rao; Tao Feng; Chufan Wu; Hanmei Lou
Journal:  Radiat Oncol       Date:  2022-10-20       Impact factor: 4.309

3.  A comparative dosimetric study of cervical cancer patients with para-aortic lymph node metastasis treated with volumetric modulated arc therapy vs. 9-field intensity-modulated radiation therapy.

Authors:  Yaqin Wu; Biqing Zhu; Jingjing Han; Hanzi Xu; Zhen Gong; Yongqin Yang; Jian Huang; Emei Lu
Journal:  Ann Transl Med       Date:  2019-11

4.  Treatment Outcome and Prognosis Factors of FIGO 2018 Stage III Cervical Cancer Patients Treated with Definitive Concurrent Chemoradiation in Vietnam.

Authors:  Huyen Thi Phung; Minh Cong Truong; Long Thanh Nguyen; Anh Thi Van Dang; Thanh Ha Vu; Hoa Thi Nguyen
Journal:  Asian Pac J Cancer Prev       Date:  2021-03-01

5.  Prognostic Significance of Clinicopathological Factors Influencing Overall Survival and Event-Free Survival of Patients with Cervical Cancer: A Systematic Review and Meta-Analysis.

Authors:  Shengwei Kang; Junxiang Wu; Jie Li; Qing Hou; Bin Tang
Journal:  Med Sci Monit       Date:  2022-03-09

Review 6.  The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies.

Authors:  Richard Pötter; Kari Tanderup; Christian Kirisits; Astrid de Leeuw; Kathrin Kirchheiner; Remi Nout; Li Tee Tan; Christine Haie-Meder; Umesh Mahantshetty; Barbara Segedin; Peter Hoskin; Kjersti Bruheim; Bhavana Rai; Fleur Huang; Erik Van Limbergen; Max Schmid; Nicole Nesvacil; Alina Sturdza; Lars Fokdal; Nina Boje Kibsgaard Jensen; Dietmar Georg; Marianne Assenholt; Yvette Seppenwoolde; Christel Nomden; Israel Fortin; Supriya Chopra; Uulke van der Heide; Tamara Rumpold; Jacob Christian Lindegaard; Ina Jürgenliemk-Schulz
Journal:  Clin Transl Radiat Oncol       Date:  2018-01-11

Review 7.  Treatment Strategies and Prognostic Factors of 2018 FIGO Stage IIIC Cervical Cancer: A Review.

Authors:  Fengying Qin; Huiting Pang; Tao Yu; Yahong Luo; Yue Dong
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

8.  Clinical significance of lymph node size in locally advanced cervical cancer treated with concurrent chemoradiotherapy.

Authors:  Jinju Oh; Ki Ho Seol; Youn Seok Choi; Jeong Won Lee; Jin Young Bae
Journal:  Yeungnam Univ J Med       Date:  2019-02-21

9.  A Risk Stratification for Patients with Cervical Cancer in Stage IIIC1 of the 2018 FIGO Staging System.

Authors:  Xiaoliang Liu; Weiping Wang; Ke Hu; Fuquan Zhang; Xiaorong Hou; Junfang Yan; Qingyu Meng; Ziqi Zhou; Zheng Miao; Hui Guan; Jiabin Ma; Jing Shen; Hongnan Zhen; Wenhui Wang
Journal:  Sci Rep       Date:  2020-01-15       Impact factor: 4.379

10.  Extended field or pelvic intensity-modulated radiotherapy with concurrent cisplatin chemotherapy for the treatment of post-surgery multiple pelvic lymph node metastases in cervical cancer patients: a randomized, multi-center phase II clinical trial.

Authors:  Weiming Luo; Yunhai Li; Guihao Ke; Xiaohua Wu; Xiao Huang
Journal:  Transl Cancer Res       Date:  2021-01       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.